Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis

Alimentary Pharmacology and Therapeutics

Volumn 11, Issue 5, 1997, Pages 853-858

  Kruis, W ^a,g   Schutz E ^a,b,c   Fric, P ^d   Fixa, B ^e   Judmaier, G ^f   Stolte, M ^c  

^a UNIVERSITY OF COLOGNE   (Germany)

^b Castra Regina Centre   (Germany)

^c Laboratory of Gastroenterology   (Czech Republic)

^d CHARLES UNIVERSITY   (Czech Republic)

^e UNIVERSITY OF INNSBRUCK   (Austria)

^f Pathological Institute   (Germany)

^g Evangelisches Krankenhaus Kalk   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MESALAZINE; NONSTEROID ANTIINFLAMMATORY AGENT; PROBIOTIC AGENT; CORTICOSTEROID; SALICYLIC ACID DERIVATIVE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ESCHERICHIA COLI; FEMALE; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; ULCERATIVE COLITIS; DIARRHEA; FLATULENCE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RECURRENCE RISK; REMISSION; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLITIS, ULCERATIVE; DOUBLE-BLIND METHOD; ESCHERICHIA COLI; FEMALE; HUMANS; MALE; MESALAMINE; MIDDLE AGED; PROBIOTICS; RECURRENCE;

EID: 0030611915     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.1997.00225.x     Document Type: Article

References (26)

1. Williams CN. Overview of 5-ASA in therapy of inflammatory bowel disease. Can J Gastroenterol 1994; 8: 379-82.
2. Allgayer H. Sulfasalazine and 5-ASA compounds. Gastroenterol Clin N Amer 1992; 21: 643-58.
3. Das KM. Eastwood MA. McManus JPA, Sircus W. Adverse reactions during salicylazosulphapyridine therapy and the relation with drug metabolism and acetylator phenotype. N Engl J Med 1973; 289: 491-5.
4. Dignass A, Layer P. Sulphasalazine, mesalazine and other 5ASA derivatives. In: Fleig WE, ed. Inflammatory Bowel Diseases: New Developments and Standards. Dordrecht: Kluwer Academic Publishers. 1995: 183-92.
5. Sartor RB. Current concepts of the etiology and pathogenesis of . Crohn's disease and ulcerative colitis. Gastroenterol Clin N Am 1995; 24: 475-507.
6. Burke DA. Axon ATR. Ulcerative colitis and £. coli with adhesive properties. J Clin Pathol 1987; 40: 782-6.
7. Von Wulffen H. Rüssmann H. Karch H. et al. Verotoxin-producing Escherichia coli 02: H5 isolated from patients with ulcerative colitis. Lancet 1989: i: 1449-50.
8. Sonnenborn U, Greinwald R. Escherichia coli im menschlichen Darm: nützlich, schädlich oder unbedeutend? Dtsch med Wschr 1990; 115:906-12.
9. Lodinova-Zadnikovâ R, Tlaskalovâ-Hogenovâ H, Sonnenborn U. Local and serum antibody response in fullterm and premature infants after artificial colonization of the intestine with E. coli strain Nissle 1917 (Mutaflor). Pediatr Allergy Immunol 1992; 3: 43-8.
10. Malchow H, Sonnenborn U, Greinwald R, Körner A. Colonization of adults by a non-pathogenic Escherichia coli strain administered after gut decontamination. Microec Health Distal, in press.
11. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) vs. sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. Br Med J 1989; 298: 82-6.
12. Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokin Biopharm 1987; 15: 657-80.
13. Turunen U, Färkkilä M, Hakala K, et al. A double-blind, placebo controlled six-month ciprofloxacin treatment improves prognosis in ulcerative colitis. Gastroenterology 1994; 106: 786(Abstract).
14. Burke DA, Axon ATR. Adhesive Escherichia coli in inflammatory bowel disease and infective diarrhoea. Br Med J 1988; 297: 102-4.
15. Bennet JD, Brinkman M. Treatment of ulcerative colitis by implantation of normal colonie flora. Lancet 1989; i: 164.
16. Schwan A, Sjölin S, Trottestam U, Aronsson B. Relapsing Clostridiwn difficile enterocolitis cured by rectal infusion of normal faeces. Scand J Infect Dis 1984; 16: 211-5.
17. Gorbach S, Chang T, Golding B. Successful treatment of relapsing Clostridiiim difficile colitis with Lactobacillus GG. Lancet 1987: ii: 1519.
18. Tvede M, Rask-Madsen J. Bacteriotherapy for chronic relapsing Clostridium difficile diarrhoea in six patients. Lancet 1989; i: 1156-60.
19. Nissle A. Übersicht über die Bedeutung bakteriologischer Stuhluntersuchungen bei nichtinfektiösen Darmerkrankungen. Arch Hyg Bakt 1930; 103: 124-31.
20. Nissle A. Das Problem der Dysbakterie des Dickdarms und ihrer Behandlung. Klin Wschr 1932; 13: 1456-9.
21. Schröder H. Entwicklung der aeroben Darmflora bei Neugeborenen nach Kolonisierung mit dem E.-coli-Stamm. Nissle 1917. Der Kinderarzt 1992; 23: 1619-25.
22. Hockertz S. The immunomodulating effect of killed apathogenic Escherichia coli, strain Nissle 1917, on the macrophage system. Arzneim-Forsch/Drug Res 1991; 41:1108-12.
23. Ireland A, Mason CH, Jewell DP. Controlled trial comparing olsalazine and sulphasalazine for the maintenance treatment of ulcerative colitis. Gut 1988; 29: 835-7.
24. Kiilerich S, Ladefoged K, Rannem T, Ranlov PJ, and The Danish Olsalazine Study Group. Prophylactic effects of olsalazine vs. sulphasalazine during 12 months maintenance treatment of ulcerative colitis. Gut 1992; 33: 252-5.
25. Kruis VV, Judmaier G. Kayasseh L, et al Double-blind dosefinding study of olsalazine vs. sulphasalazine as maintenance therapy for ulcerative colitis. Eur J Gastroenterol Hepatol 1995; 7: 391-6.
26. Miner P, Hanauer S. Robinson M, Schwartz J, Arora S, Pentasa UC maintenance study group. Safety and efficacy of controlledrelease mesalamine for maintenance of remission in ulcerative colitis. Dig Dis Sei 1995; 40: 296-304.